A PBPK model describing the pharmacokinetics of γ-HBCD exposure in mice.


Journal

Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 23 04 2021
revised: 10 07 2021
accepted: 09 08 2021
pubmed: 15 8 2021
medline: 6 10 2021
entrez: 14 8 2021
Statut: ppublish

Résumé

The brominated flame retardant, hexabromocyclododecane (HBCD), is added-but not bound-to consumer products and is eventually found in the environment and human tissues. Commercial-grade HBCD mixtures contain three major stereoisomers, alpha (α), beta (β), and gamma (γ), that are typically at a ratio of 12%:6%:82%, respectively. Although HBCD is widely used, the toxicological effects from its exposure in humans are not clearly understood. Using a physiologically based pharmacokinetic (PBPK) model could help improve our understanding of the toxicity of HBCD. The aim of this work was to develop a PBPK model, consisting of five permeability limited compartments (i.e., brain, liver, adipose tissue, blood, and rest of the body), to evaluate the pharmacokinetics of γ-HBCD in C57BL/6 mice. Physiological parameters related to body size, organ weights, and blood flow were taken from the literature. All partition coefficients were calculated based on the log K

Identifiants

pubmed: 34390738
pii: S0041-008X(21)00282-9
doi: 10.1016/j.taap.2021.115678
pmc: PMC8674938
mid: NIHMS1754251
pii:
doi:

Substances chimiques

Flame Retardants 0
Hydrocarbons, Brominated 0
hexabromocyclododecane 5I9835JO3M

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

115678

Subventions

Organisme : Intramural NIH HHS
ID : ZIA BC011476
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

Environ Health Perspect. 2006 Sep;114(9):1394-400
pubmed: 16966094
Environ Res. 2008 Oct;108(2):192-8
pubmed: 18762293
Arch Toxicol. 2018 Mar;92(3):1189-1203
pubmed: 29177809
Toxicol Lett. 2003 Feb 18;138(1-2):9-27
pubmed: 12559690
Environ Int. 2003 Sep;29(6):683-9
pubmed: 12850087
Environ Health Perspect. 2017 Apr;125(4):651-659
pubmed: 27814246
Environ Health Perspect. 2004 Jan;112(1):9-17
pubmed: 14698924
Toxicol Sci. 2013 Aug;134(2):251-7
pubmed: 23733921
Environ Toxicol Pharmacol. 2006 May;21(3):317-22
pubmed: 21783674
Sci Total Environ. 2014 Jan 15;468-469:622-9
pubmed: 24061053
Compr Physiol. 2017 Sep 12;7(4):1085-1135
pubmed: 28915320
Toxicol Sci. 2003 Jan;71(1):41-52
pubmed: 12520074
Environ Sci Technol. 2016 Jan 5;50(1):89-96
pubmed: 26629593
Sci Total Environ. 2015 Aug 15;524-525:416-26
pubmed: 25933174
Environ Health Perspect. 2009 Dec;117(12):1953-8
pubmed: 20049217
Environ Int. 2003 Sep;29(6):829-39
pubmed: 12850099
Biomed Res Int. 2020 Feb 27;2020:7502578
pubmed: 32190678
Neurotoxicol Teratol. 2015 Nov-Dec;52(Pt B):162-9
pubmed: 26073293
Environ Res. 2014 Aug;133:170-7
pubmed: 24949816
Food Chem Toxicol. 2019 Nov;133:110785
pubmed: 31449896
Chemosphere. 2007 Jun;68(5):940-50
pubmed: 17346772
Toxicol Sci. 2010 Oct;117(2):282-93
pubmed: 20562218
J Toxicol Environ Health. 1982 Jan;9(1):107-18
pubmed: 6174734
In Silico Pharmacol. 2016 Dec;4(1):3
pubmed: 26932471
Environ Int. 2009 Aug;35(6):870-6
pubmed: 19344952
Neurotoxicol Teratol. 2014 Sep-Oct;45:34-43
pubmed: 24995466
Reprod Toxicol. 2018 Sep;80:105-116
pubmed: 29935226
Environ Int. 2013 May;55:33-42
pubmed: 23518385
Nutr Metab (Lond). 2004 Nov 05;1(1):12
pubmed: 15530168
Toxicol Sci. 2011 Sep;123(1):256-63
pubmed: 21705717
AAPS J. 2009 Jun;11(2):323-34
pubmed: 19430911
Neuroimage. 2011 Jan 1;54(1):80-9
pubmed: 20656042
Gerontology. 2012;58(1):15-23
pubmed: 21135534
Early Hum Dev. 1979 Mar;3(1):79-83
pubmed: 118862
Environ Toxicol Pharmacol. 2015 Jul;40(1):241-58
pubmed: 26164742
Pharm Res. 2005 Nov;22(11):1863-70
pubmed: 16132351
Front Pharmacol. 2012 Mar 29;3:46
pubmed: 22479246
Diabetes. 1997 May;46(5):860-7
pubmed: 9133556
Environ Sci Technol. 2006 Jun 15;40(12):3679-88
pubmed: 16830527
Toxicol Sci. 2018 May 1;163(1):152-169
pubmed: 29385628
J Toxicol Environ Health A. 2007 Jun;70(12):1027-37
pubmed: 17497414
Int J Obes (Lond). 2014 Aug;38(8):1019-26
pubmed: 24166067
Environ Sci Technol. 2008 Jan 15;42(2):459-64
pubmed: 18284147
J Environ Public Health. 2011;2011:417980
pubmed: 21647350
Circ Res. 2020 Aug 28;127(6):793-795
pubmed: 32853094
Toxicol Sci. 2002 May;67(1):98-103
pubmed: 11961221
Toxicol Sci. 2003 Mar;72(1):3-18
pubmed: 12604830
Int J Obes Relat Metab Disord. 2002 Jan;26(1):1-5
pubmed: 11791140
Inhal Toxicol. 2008 Feb;20(4):361-73
pubmed: 18302045
Environ Health Perspect. 2012 Sep;120(9):1260-4
pubmed: 22647707
Inhal Toxicol. 2003 May;15(6):589-617
pubmed: 12692732
Regul Toxicol Pharmacol. 2016 Feb;74 Suppl:S1-13
pubmed: 26724268
Environ Health Perspect. 2005 Dec;113(12):1666-8
pubmed: 16330344
Environ Health Perspect. 2013 Feb;121(2):a61
pubmed: 23380189
Toxicol Appl Pharmacol. 2021 Oct 1;428:115678
pubmed: 34390738
Cerebellum. 2011 Mar;10(1):22-31
pubmed: 20967578
Toxicol In Vitro. 2018 Mar;47:213-227
pubmed: 29203341
Toxicol Sci. 2011 Jun;121(2):234-44
pubmed: 21441408
Neurochem Int. 2003 Sep-Oct;43(4-5):533-42
pubmed: 12742101
Chemosphere. 2009 Mar;74(11):1485-9
pubmed: 19124143
J Agric Food Chem. 2012 Aug 29;60(34):8528-34
pubmed: 22881704
Environ Pollut. 2015 Apr;199:26-34
pubmed: 25618363
Environ Toxicol Pharmacol. 2017 Mar;50:167-174
pubmed: 28214749
Toxicology. 2014 Jul 3;321:1-12
pubmed: 24680724
Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
pubmed: 9249929
Toxicol Lett. 2009 Feb 25;185(1):63-72
pubmed: 19111915
Chemosphere. 2018 Sep;207:70-77
pubmed: 29772426
Environ Sci Technol. 2011 Oct 15;45(20):8613-23
pubmed: 21913722
Toxicol Sci. 2004 Jul;80(1):115-33
pubmed: 15056810
Toxicol Mech Methods. 2006;16(8):395-403
pubmed: 20021013
Circ Res. 2019 May 10;124(10):1505-1518
pubmed: 31071007

Auteurs

Claude Emond (C)

BioSimulation Consulting Inc., Newark, DE, USA; School of Public Health, Department of Environmental and Occupational Health, University of Montreal, Quebec, Canada. Electronic address: claude.emond@biosmc.com.

Michael J DeVito (MJ)

National Institute of Environmental Health Sciences, National Toxicology Program, Research Triangle Park, NC, USA.

Linda S Birnbaum (LS)

National Cancer Institute, Research Triangle Park, NC, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH